CompletedPhase 2NCT02762084
Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients
Studying Gorlin syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- PellePharm, Inc.
- Principal Investigator
- John Lear, MDManchester Royal Infirmary
- Intervention
- Patidegib(drug)
- Enrollment
- 17 enrolled
- Eligibility
- 18-85 years · All sexes
- Timeline
- 2016 – 2017
Study locations (2)
- Royal London Hospital, London, United Kingdom
- Manchester Royal Infirmary, Manchester, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02762084 on ClinicalTrials.govOther trials for Gorlin syndrome
Additional recruiting or active studies for the same condition.